(-)-Englerin A analogs as anti-cancer compounds

Unique Technology Offer
- Novel analog compounds based on the scaffold of the natural product (-)-Englerin A have been developed and tested in vitro.
- Compounds can be prepared using geraniol as a starting materials.
- Enhanced anti-cancer activity (with respect to natural product)
- Stage of development: 18 analogs have been tested in the laboratory within the NCI 60 cell line screening program (in vitro analysis of cancer cell growth inhibition). Suggested mechanism of action.

Technology concept

Value Proposition
- Compounds are highly selective for certain types of cancers, which means a potential for significantly lower side-effects than currently available therapies. (targeted cancer therapy)
- IP can be offered along with other IP. Strong IP portfolio around the technology.
- Compounds are highly active in cancer growth inhibition at low concentrations.

Business opportunity
- Global market for Renal Cancer Carcinoma (RCC) is to reach the value of 3 billion dollars in 2017.
- CAGR of 17% for renal cancer drugs in Asia Pacific
- High market share forecast due to specific profile and singular mechanism of action
- 90,000 cases of RCC are detected in Europe each year.

Licensing Opportunity
- Partner for joint development and commercialisation of applications is sought.
- Global licensing rights for the catalyst and methods are available.
- Regional licensing deals will be considered.
- Flexible licensing strategy related to development milestones.

Further information:
National Cancer Institute Technology Transfer Center United States of America
https://ttc.nci.nih.gov/
http://www.ott.nih.gov/

ICIQ is a not-for-profit foundation focused on carrying out research of excellence in the fields of chemistry, catalysis and nanosciences. ICIQ is also engaged in transferring the results of research to the private sector through a flexible partnering and licensing strategy, thereby contributing to the knowledge economy.